Second, we found that TLR4 ligands activate STAT3 through MYD88 (myeloid differentiation primary response gene 88) and TRIF (TIR-domain-containing adapter-inducing interferon-β) in melanoma cells and promote STAT3-mediated cellular events in melanoma progression. This evidence concerns the gene MYD88 and melanoma.